Enanta Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Se prevé un crecimiento anual de los beneficios y los ingresos de Enanta Pharmaceuticals de 7.8% y 1.6% por año respectivamente. Se prevé que el BPA crezca en un 15.1% al año. Se espera que la rentabilidad financiera sea de -62.9% en 3 años.

Información clave

7.8%

Tasa de crecimiento de los beneficios

15.1%

Tasa de crecimiento del BPA

Crecimiento de los beneficios de Biotechs	24.1%
Tasa de crecimiento de los ingresos	1.6%
Rentabilidad financiera futura	-62.9%
Cobertura de analistas	Good
Última actualización	09 Feb 2024

Actualizaciones recientes sobre el crecimiento futuro

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25

Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Feb 11

Previsiones de crecimiento de beneficios e ingresos

NasdaqGS:ENTA - Estimaciones futuras de los analistas y datos financieros pasados (USD Millions)
Fecha	Ingresos	Beneficios	Flujo de caja libre	Flujo de caja operativo	Núm. de analistas medio
9/30/2026	73	-118	-190	N/A	6
9/30/2025	73	-116	-125	-111	8
9/30/2024	69	-110	-123	-92	8
12/31/2023	74	-138	-99	-93	N/A
9/30/2023	79	-134	-112	-103	N/A
6/30/2023	81	-132	-106	-97	N/A
3/31/2023	81	-125	-102	-95	N/A
12/31/2022	82	-121	-112	-107	N/A
9/30/2022	86	-122	-87	-85	N/A
6/30/2022	89	-120	-91	-90	N/A
3/31/2022	92	-112	-91	-90	N/A
12/31/2021	93	-101	-69	-68	N/A
9/30/2021	97	-79	-71	-70	N/A
6/30/2021	97	-84	-65	-64	N/A
3/31/2021	94	-74	-40	-39	N/A
12/31/2020	102	-58	-21	-20	N/A
9/30/2020	122	-36	6	7	N/A
6/30/2020	150	2	30	31	N/A
3/31/2020	176	24	35	38	N/A
12/31/2019	188	34	48	54	N/A
9/30/2019	205	46	66	71	N/A
6/30/2019	221	65	85	91	N/A
3/31/2019	234	78	88	93	N/A
12/31/2018	238	86	52	55	N/A
9/30/2018	207	72	26	29	N/A
6/30/2018	215	81	56	58	N/A
3/31/2018	166	52	47	49	N/A
12/31/2017	131	34	52	54	N/A
9/30/2017	103	18	N/A	53	N/A
6/30/2017	40	-21	N/A	-7	N/A
3/31/2017	46	-13	N/A	-4	N/A
12/31/2016	50	-10	N/A	9	N/A
9/30/2016	88	22	N/A	36	N/A
6/30/2016	90	29	N/A	36	N/A
3/31/2016	87	33	N/A	23	N/A
12/31/2015	132	63	N/A	112	N/A
9/30/2015	161	79	N/A	77	N/A
6/30/2015	149	68	N/A	74	N/A
3/31/2015	180	116	N/A	123	N/A
12/31/2014	124	82	N/A	20	N/A
9/30/2014	48	34	N/A	20	N/A
6/30/2014	46	35	N/A	23	N/A
3/31/2014	6	-19	N/A	-18	N/A
12/31/2013	5	-19	N/A	-4	N/A
9/30/2013	32	-7	N/A	11	N/A
6/30/2013	33	-3	N/A	11	N/A

Previsiones de crecimiento futuro de los analistas

Ingresos vs. Tasa de ahorro: Se prevé que ENTA siga sin ser rentable en los próximos 3 años.

Beneficios vs. Mercado: Se prevé que ENTA siga sin ser rentable en los próximos 3 años.

Beneficios de alto crecimiento: Se prevé que ENTA siga sin ser rentable en los próximos 3 años.

Ingresos vs. Mercado: Se prevé que los ingresos (1.6% al año) de ENTA crezcan más despacio que el mercado de US (8.1% al año).

Ingresos de alto crecimiento: Se prevé que los ingresos 1.6% al año) de ENTA crezcan más despacio que 20% al año.

Previsiones de crecimiento de los beneficios por acción

Rentabilidad financiera futura

ROE futura: ENTA se prevé que no sea rentable en 3 años.

Enanta Pharmaceuticals Crecimiento futuro

Future controles de criterios 0/6

Información clave

Actualizaciones recientes sobre el crecimiento futuro

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 10% to US$21.38

Consensus revenue estimates decrease by 27%, EPS upgraded

Price target decreased by 11% to US$24.38

Price target decreased by 7.7% to US$27.89

Consensus revenue estimates increase by 13%

Recent updates

Enanta Pharmaceuticals, Inc. to Report Q2, 2024 Results on May 06, 2024

Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to US$21.38

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold US$139k worth of stock

Independent Director notifies of intention to sell stock

President recently sold US$70k worth of stock

Consensus revenue estimates decrease by 27%, EPS upgraded

New minor risk - Share price stability

Price target decreased by 11% to US$24.38

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Price target decreased by 7.7% to US$27.89

Consensus revenue estimates increase by 13%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

Consensus revenue estimates fall by 25%

Insufficient new directors

Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Consensus estimates of losses per share improve by 18%

Price target decreased by 15% to US$57.40

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

Senior VP exercised options to buy US$245k worth of stock.

President notifies of intention to sell stock

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Consensus revenue estimates fall by 34%

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023

President exercised options and sold US$919k worth of stock

Consensus revenue estimates fall by 10%

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023

Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta starts mid-stage trial of EDP-938 for RSV infection

Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022

Price target increased to US$77.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer

Enanta Pharma FQ3 2022 Earnings Preview

Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta Pharmaceuticals, Inc.(NasdaqGS:ENTA) dropped from Russell 2000 Growth-Defensive Index

Price target decreased to US$69.80

Enanta Pharmaceuticals Reports Topline Data from the RSVP Study of EDP-938 in Otherwise Healthy Adults with Community-Acquired Respiratory Syncytial Virus (RSV)

Enanta: Slow Drip

Second quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q2, 2022 Results on May 09, 2022

Enanta Pharmaceuticals, Inc. Receives FDA Fast Track Designation for EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-235, its Oral 3CL Protease Inhibitor Specifically Designed for the Treatment and Prevention of COVID-19

Enanta Pharmaceuticals, Inc. announced delayed 10-Q filing

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Consensus revenue estimates fall by 11%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook